他汀类药物致横纹肌溶解风险的药物警戒比较研究
该研究利用WHO药物警戒数据库VigiBase®,比较七种他汀(除外西立伐他汀)在成人中报告横纹肌溶解的风险。男性、74岁以上及存在药物相互作用时风险更高。
要点
- 辛伐他汀横纹肌溶解报告风险在七种他汀中最高,ROR=2.20(95%CI 2.11-2.29)。
- 男性、年龄大于74岁及合并药物相互作用者风险更高。
- 临床应关注辛伐他汀及高危人群的横纹肌溶解监测。
核心结论
- 辛伐他汀相比其他他汀与更高的横纹肌溶解报告风险相关,ROR=2.20(95%CI 2.11-2.29)。
主要发现
- 男性、年龄大于74岁以及存在药物相互作用时横纹肌溶解报告风险更高。
关键数值与推荐
- 风险以报告比值比(ROR,95%CI)表示,辛伐他汀ROR=2.20(95%CI 2.11-2.29)。
临床怎么用
- 临床使用辛伐他汀时应加强横纹肌溶解监测,尤其对男性、74岁以上及合并药物相互作用的患者。
局限性
- 本研究为基于自发报告数据库的药物警戒研究,结果反映报告风险而非确证因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rhabdomyolysis is a serious adverse drug reaction of statins. There are few studies comparing the risk of rhabdomyolysis between the different statins. Using the WHO pharmacovigilance database, VigiBase®, we compared the risk of rhabdomyolysis reporting of seven statins (atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin and simvastatin, with cerivastatin excluded). All reports of rhabdomyolysis in VigiBase® in adults with statins until 31 December 2022 were included. Results are expressed as reporting odds ratio (ROR, 95% CI). Among 10 657 reports with rhabdomyolysis with statins, simvastatin was the highest risk statin in comparison with others: ROR = 2.20 (2.11-2.29). The risk was higher in men, older than 74 years and in cases of drug interactions.
引用
- Montastruc JL. Rhabdomyolysis and statins: A pharmacovigilance comparative study between statins. Br J Clin Pharmacol. 2023. PMID: 37186323. doi:10.1111/bcp.15757
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。